跳转至内容
Merck

PHR1362

Supelco

乙酸钙

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

乙酸钙

登录查看公司和协议定价


About This Item

线性分子式:
(CH3CO2)2Ca
CAS号:
分子量:
158.17
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material
pharmaceutical secondary standard

品質等級

agency

traceable to USP 1086334

API 家族

calcium acetate

CofA

current certificate can be downloaded

技術

HPLC: suitable
gas chromatography (GC): suitable

雜質

~1% Acetic acid

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-30°C

SMILES 字串

CC(=O)O[Ca]OC(C)=O

InChI

1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2

InChI 密鑰

VSGNNIFQASZAOI-UHFFFAOYSA-L

正在寻找类似产品? 访问 产品对比指南

一般說明

Calcium Acetate belongs to the group of calcium salts, widely used as phosphorus binders in patients with chronic renal failure.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

應用

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

腳註

To see an example of a Certificate of Analysis for this material enter LRAA1466 in the slot below. This is an example certificate only and may not be the lot that you receive.

相關產品

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel T Grima et al.
Current medical research and opinion, 29(2), 109-115 (2012-12-12)
The avoidance of hospitalizations and the maintenance of in-center dialysis sessions in patients receiving dialysis for end-stage renal disease (ESRD) have obvious benefits to patients, dialysis providers and payers. Benefits include better continuity of care, better patient outcomes, improved quality
Leonardo V Riella et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 57(4), 641-645 (2011-02-22)
Hypophosphatemia is a common complication after kidney transplant, affecting >90% of patients. However, no specific recommendations for phosphate repletion exist for transplant recipients. We report a case of a 70-year-old highly sensitized woman with end-stage renal disease caused by diabetic
Meagan L Harless et al.
Environmental toxicology and chemistry, 30(7), 1637-1641 (2011-04-08)
Widespread and intensive application of road deicers, primarily road salt (NaCl), in North America threatens water quality and the health of freshwater ecosystems. Intensive use of NaCl can be harmful to sensitive members of freshwater ecosystems such as amphibians. Detection
Alastair J Hutchison et al.
Nature reviews. Nephrology, 7(10), 578-589 (2011-09-07)
The ideal serum level of phosphate in patients on dialysis, and the benefits of controlling levels of phosphate in serum remain unclear despite observational studies that associate phosphate levels with mortality. In the absence of robust data from trials, current
Rodrigo B de Oliveira et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 28(10), 2510-2517 (2013-08-27)
Mineral bone disorder (MBD) is an early complication of chronic kidney disease (CKD), with complex interactions in the bone-kidney-energy axis. These events lead to impaired bone remodelling, which in turn is associated with cardiovascular disease. Recently, we reported on a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门